Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects:

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

Subjects:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... by Claire M. Douglas (21238238)

Subjects:

Combination of intraperitoneal and intratumoral administration of vitamin D3 is more effective in reducing the EAC tumor volume compared to just i.p. administration: by Vidya G. Bettada (22208808)

“…Administration of cisplatin (2.5 mg/Kg) and vitamin D3 (125 µg/Kg) significantly decreased the vessel density (CD31) compared to the tumor control group.…”

(a to g) Administration of vitamin D3 increased serum phosphorus and triglycerides. by Vidya G. Bettada (22208808)

Treatment of cancer cells with vitamin D3 induced death <i>a.</i> by Vidya G. Bettada (22208808)

Expression of Caspase-3 in HCT 116 and Hep 3B: <i>2A. and 2B.</i> by Vidya G. Bettada (22208808)

Treatment with vitamin D3 reduced the viability of cancer cell lines: <i>1A & 1B.</i> by Vidya G. Bettada (22208808)

“…The bars represent the average of three independent experiments with the significance (P) determined by One-Way ANOVA at each time point. …”

Vitamin D3, but not the Cisplatin, could moderately reduce STZ-induced hyperglycemia in mice (a) Schematic representation of experimental protocol followed in the study: After accl... by Vidya G. Bettada (22208808)

AO/EtBr Staining of Cancer cell lines: <i>To check whether vitamin D3 promoted cell death in cancer cells, a dual staining protocol was implemented as detailed in the methods secti... by Vidya G. Bettada (22208808)

Annual incidence of insomnia disorder (ICD-CODE: G47) Bar: rate of insomnia disorder relative to all patients; Line: average number of outpatient visits for patients with insomnia... by Mingee Choi (15250732)

Subjects:

Distribution of non-pharmacological treatment related to insomnia disorder (2002–2019). by Mingee Choi (15250732)

Subjects:

Detailed treatment status of patients who did not receive non-pharmacological treatment at first diagnosis but received it later. by Mingee Choi (15250732)

Subjects:

Mean interval from initial diagnosis to initiation of non-pharmacological treatment by year. by Mingee Choi (15250732)

Subjects:

General information of patient who diagnosis insomnia disorder (N = 518,119). by Mingee Choi (15250732)

Subjects:

Detailed treatment status of people who received non- pharmacological treatment at first diagnosis. by Mingee Choi (15250732)

Subjects:

Treatment at first diagnosis of insomnia disorder (%). by Mingee Choi (15250732)

Subjects:

Comparison of the cohesion ranges of different food categories under IDDSI levels. by Muxi Chen (9294270)

Subjects: